OpenAI Acquires Orchestra Bio to Scale Life Sciences Capabilities
AI-generated image · Bay Street Wire
The acquisition integrates AI agent technology into OpenAI's Rosalind model and workbench, targeting the pharmaceutical sector.
OpenAI announced Tuesday the acquisition of Orchestra Bio, a four-year-old AI biotech software startup, as TechCrunch first reported. While the financial terms of the transaction were not disclosed, TechCrunch reports that Orchestra Bio had raised approximately $20 million as of 2025 from investors including 8VC, Atria, and Andreessen Horowitz.
Orchestra Bio specializes in AI agents designed to streamline drug discovery operations, specifically handling clinical trial scheduling and financial tracking. According to OpenAI, the startup's technology and personnel will be integrated into the development of the Rosalind AI model for life sciences research and the Rosalind Workbench, a tool used by researchers for result analysis and experiment planning.
OpenAI noted that it has already secured major pharmaceutical customers for the Rosalind platform, specifically naming Novo Nordisk and Moderna. TechCrunch characterizes the move as part of a broader trend where leading AI labs, including Anthropic and OpenAI, are developing specialized software for major industries such as pharma.